SI2086576T1 - Proteini H molekule nukleinske kisline in vektorji ki jih kodirajo in njihova medicinska uporaba - Google Patents

Proteini H molekule nukleinske kisline in vektorji ki jih kodirajo in njihova medicinska uporaba

Info

Publication number
SI2086576T1
SI2086576T1 SI200731036T SI200731036T SI2086576T1 SI 2086576 T1 SI2086576 T1 SI 2086576T1 SI 200731036 T SI200731036 T SI 200731036T SI 200731036 T SI200731036 T SI 200731036T SI 2086576 T1 SI2086576 T1 SI 2086576T1
Authority
SI
Slovenia
Prior art keywords
protein
nucleic acid
acid molecule
medical use
vectors encoded
Prior art date
Application number
SI200731036T
Other languages
English (en)
Slovenian (sl)
Inventor
Eric M Vaughn
Paulino Carlos Gonzalez-Hemandez
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of SI2086576T1 publication Critical patent/SI2086576T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200731036T 2006-10-27 2007-10-26 Proteini H molekule nukleinske kisline in vektorji ki jih kodirajo in njihova medicinska uporaba SI2086576T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP07863555.4A EP2086576B8 (en) 2006-10-27 2007-10-26 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Publications (1)

Publication Number Publication Date
SI2086576T1 true SI2086576T1 (sl) 2012-11-30

Family

ID=39325469

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731036T SI2086576T1 (sl) 2006-10-27 2007-10-26 Proteini H molekule nukleinske kisline in vektorji ki jih kodirajo in njihova medicinska uporaba

Country Status (18)

Country Link
US (3) US8202967B2 (enExample)
EP (1) EP2086576B8 (enExample)
JP (2) JP5442442B2 (enExample)
KR (2) KR20150041200A (enExample)
AU (1) AU2007308869B2 (enExample)
BR (1) BRPI0718183B8 (enExample)
CA (1) CA2664914C (enExample)
CO (1) CO6210831A2 (enExample)
DK (1) DK2086576T3 (enExample)
ES (1) ES2391123T3 (enExample)
MX (1) MX2009004243A (enExample)
MY (1) MY150226A (enExample)
PL (1) PL2086576T3 (enExample)
PT (1) PT2086576E (enExample)
RU (1) RU2479589C2 (enExample)
SG (1) SG176419A1 (enExample)
SI (1) SI2086576T1 (enExample)
WO (1) WO2008052173A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053446A2 (en) * 2005-10-28 2007-05-10 Boehringer Ingelheim Vetmedica, Inc Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
EP2367566B2 (en) 2008-11-28 2019-11-27 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
NZ602217A (en) * 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
CA2813078A1 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
ES2689878T3 (es) * 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
JP7337921B2 (ja) * 2018-11-06 2023-09-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 鳥インフルエンザウイルスｈ５亜型に対する免疫原性組成物
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0528859B1 (en) 1990-04-24 1998-01-21 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
EP0561034B1 (en) 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
EP0871755A1 (en) 1995-03-23 1998-10-21 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
EP2085468A1 (en) 2000-04-28 2009-08-05 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
WO2002003872A2 (en) 2000-07-11 2002-01-17 Johns Hopkins University Application of photochemotherapy for the treatment of cardiac arrhythmias
JPWO2002062381A1 (ja) * 2001-02-05 2004-06-03 久光製薬株式会社 バキュロウイルスベクターワクチン
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US20040146533A1 (en) 2002-08-27 2004-07-29 Miller Timothy J. Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN1816903B (zh) 2003-07-04 2011-10-05 Nxp股份有限公司 前体溶液及其制备和使用方法
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
JP4980896B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
EP1877088B1 (en) * 2005-04-11 2014-12-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine against pandemic strains of influenza viruses
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
SI1937301T1 (sl) 2005-10-18 2015-08-31 Novavax, Inc. Funkcionalni influenčnemu virusu podobni delci (VLP)
WO2007053446A2 (en) 2005-10-28 2007-05-10 Boehringer Ingelheim Vetmedica, Inc Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CN102869379B (zh) 2010-04-30 2015-04-15 淡马锡生命科学研究院有限公司 H5n1谱系的通用疫苗
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento

Also Published As

Publication number Publication date
EP2086576B8 (en) 2015-02-18
RU2479589C2 (ru) 2013-04-20
BRPI0718183B8 (pt) 2022-05-24
PT2086576E (pt) 2012-10-11
US8202967B2 (en) 2012-06-19
ES2391123T3 (es) 2012-11-21
US20140050755A1 (en) 2014-02-20
KR101520307B1 (ko) 2015-05-29
US9375469B2 (en) 2016-06-28
WO2008052173A3 (en) 2008-11-13
EP2086576A2 (en) 2009-08-12
DK2086576T3 (da) 2012-10-15
JP2014012008A (ja) 2014-01-23
MX2009004243A (es) 2009-05-14
BRPI0718183B1 (pt) 2020-03-17
BRPI0718183A2 (pt) 2013-11-05
RU2009119597A (ru) 2010-12-10
EP2086576B1 (en) 2012-07-18
JP2010508030A (ja) 2010-03-18
EP2086576A4 (en) 2011-01-19
MY150226A (en) 2013-12-31
CA2664914A1 (en) 2008-05-02
WO2008052173A2 (en) 2008-05-02
KR20090078362A (ko) 2009-07-17
JP5442442B2 (ja) 2014-03-12
AU2007308869A1 (en) 2008-05-02
AU2007308869B2 (en) 2013-10-24
US20120231027A1 (en) 2012-09-13
US8592558B2 (en) 2013-11-26
CO6210831A2 (es) 2010-10-20
CA2664914C (en) 2016-11-22
WO2008052173A8 (en) 2011-02-03
US20080193471A1 (en) 2008-08-14
PL2086576T3 (pl) 2012-12-31
WO2008052173A9 (en) 2012-03-22
KR20150041200A (ko) 2015-04-15
SG176419A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
SI2086576T1 (sl) Proteini H molekule nukleinske kisline in vektorji ki jih kodirajo in njihova medicinska uporaba
NL301339I2 (nl) L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat
IL213039A (en) Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
BRPI0917000A2 (pt) proteínas conjugadas com eficácia in vivo prolongada
DK2240595T4 (da) Glykosyleret proteinekspression i prokaryoter
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
EP1912699A4 (en) MAGNETIC CORE FOR MEDICAL INTERVENTIONS
EP2144749A4 (en) CLEANING AND BODY CARE PRODUCTS
DK2121989T3 (da) K-ras-mutationer og anti-EGFR-antistofbehandling
EP2165609A4 (en) MEANS FOR IMPROVED PANSEN FERMENTATION
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
PL2142186T3 (pl) Stosowanie oligomerów kwasu mlekowego w leczeniu zaburzeń ginekologicznych
SMT201300072B (it) Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide
EP2157096A4 (en) AMPHIPATHIC MOLECULE, MOLECULAR AGGREGATE COMPRISING THE AMPHIPATHIC MOLECULE, AND USE OF MOLECULAR AGGREGATE
FR2926020B1 (fr) Composition cosmetique et/ou dermatologique
EP1993447A4 (en) ULTRASONIC MOLECULAR SENSORS AND USES THEREOF
FI20060729A0 (fi) Ihon- tai karvanhoitokoostumus tai sen valmistuksessa käytetty puolivalmiste
BRPI0811013A2 (pt) Formulações de aminoácidos n-halogenado e métodos para limpeza e desinfecção
SI2341900T1 (sl) Medicinski proizvod in zdravljenje
BRPI0822079A2 (pt) Método, fluido de tratamento ácido, e, composição